SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline sharply through 2027 has fueled concern about pricing and CorMedixs largest revenue driver. Traders are divided: some see a lasting revenue risk, while others argue DaVitas estimate is preliminary and not a definitive forecast of CMS rates or CorMedix revenue.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos decline is being tied to an analyst price-target cut amid concerns that networking growth may be peaking and the stocks valuation could compress; the firm kept its rating unchanged. Traders are split between calling the selloff an overreaction given AI-networking demand and seeing continued technical weakness.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a fresh 52-week high has traders focused on anticipated Q3 earnings and BRIUMVIs growth, with buyout speculation and possible short covering adding to the bullish momentum. Some traders see the move as earnings-driven, while others caution that takeover talk remains unconfirmed.

First Majestic Silver Corp. engages in the production, development, exploration, and acquisition of mineral properties, with a focus on silver and gold production in North America. It owns and operates producing mines in Mexico, including the Santa Elena Silver & Gold Mine, the Los Gatos Silver Mine, the San Dimas Silver & Gold Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA, which is currently in the process of restarting. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

AG is drawing attention amid volatile silver prices and weakness across precious-metals miners, with traders pointing to rising yields and expectations of tighter Fed policy as headwinds. Some see the pullback as a buying opportunity based on long-term silver supply and demand, while others expect further downside and question when miners will recover.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,387.69. The last known price of BNB is 703.59425696 USD and is up 0.47 over the last 24 hours. It is currently trading on 3523 active market(s) with $2,735,089,335.64 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

A reported multibillion-dollar Binance security breach is driving attention, with traders focused on suspended withdrawals and concerns about exchange security and customer funds. The community debates whether Binance can cover the losses and whether BNBs limited decline understates the risk; claims of an inside job or specific perpetrators remain speculation.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is drawing attention for choppy trading around technical resistance, with traders split on whether a breakout can hold or shares will retreat toward support. Bullish options activity and optimism about parks, streaming and recent earnings compete with frustration over the stocks long-term performance.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reported Lundbeck interest in acquiring Xeris has fueled takeover speculation, with traders debating whether other buyers could emerge; the company has said it is not for sale, and no deal is confirmed. Others are focused on the upcoming quarterly results and Recorlev growth, as well as the longer-term XP-8121 Phase 3 opportunity.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention centers on upcoming CRISPR Therapeutics updates, especially CTX310 Phase 1b data and zugo-cel results, alongside earnings and Casgevy sales. Traders are divided between optimism about the clinical catalysts and frustration over the stocks persistent weakness and rangebound trading.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Positive Phase 3 results for Amgens IMDELLTRAImfinzi combination in small-cell lung cancer are driving attention, with traders pointing to the survival benefit as support for the companys oncology pipeline and recent strength. The discussion is also focused on momentum near 52-week highs ahead of quarterly results and an upcoming Sjgrens disease data presentation.

Pudgy Penguins (PENGU) is a cryptocurrency launched in 2024and operates on the Solana platform. Pudgy Penguins has a current supply of 76,724,221,264.3 with 62,860,396,090.04 in circulation. The last known price of Pudgy Penguins is 0.00754361 USD and is up 6.59 over the last 24 hours. It is currently trading on 540 active market(s) with $130,377,930.32 traded over the last 24 hours. More information can be found at https://www.pengu.pudgypenguins.com.

Pudgy Penguins

Traders are focused on PENGU testing a technical support/buying zone after rejection from a descending channel, debating whether it can bounce or break lower. Some are buying the dip and anticipating a reversal, while others warn of further downside; broader crypto moves, especially Bitcoin, are also seen as influential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?

AtaiBeckley Inc (ATAI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Lilly Builds Neuroscience into a New Long-Term Growth Driver

Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.

Jim Cramer Isn't Sure If There's Upside In This Health Care Stock

Cramer favors Howmet, remains cautious on AeroVironment, Rocket, AtaiBeckley and MP Materials, citing competition and limited upside.read more...

Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?

Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders? Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 17, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's  What You Should Know

The mean of analysts' price targets for AtaiBeckley Inc (ATAI) points to a 31.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

LLY Q2 Earnings Top, GLP-1 Drugs Fuel Growth, Sales Guidance Raised

LLY crushes Q2 earnings estimates and lifts its 2026 sales outlook as Mounjaro and Zepbound fuel strong revenue growth and newer drugs add momentum.

Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders?

Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders? Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 4, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

Will Mounjaro & Zepbound Drive Lilly's Q2 Results: Buy, Sell or Hold?

LLY is set to report Q2 results on Aug. 5, with GLP-1 drugs expected to drive growth as investors watch Foundayo's early sales.

Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower 

Equity

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%

The consensus price target hints at a 33.3% upside potential for AtaiBeckley Inc (ATAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>XBI has gained 25% this year and nearly 80% over the past 12 months, hitting its highest level since February 2021.</li><li>Biotech’s rebound is being driven by Big Pharma’s need to replace revenue threatened by looming patent expirations.</li><li>Vertex, AbbVie and GSK have each struck deals worth about $10 billion or more for late-stage or commercially ready assets.</li></ul>The AI and memory-chip rallies may have already minted their biggest winners, but biotech is mounting a breakout of its own, with the XBI biotech ETF sharply outperforming the broader market as cash-rich drugmakers race to buy promising pipelines before blockbuster patent losses begin eroding revenue.The&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> has gained 25% this year and nearly 80% over the past 12 months, eclipsing the broader market’s advance. The ETF hit its highest level since February 2021 on July 9, marking a turnaround from the prolonged biotech slump that followed the sector's pandemic-era boom.&nbsp;<img src="https://news.stocktwits-cdn.com/koyfin_20260723_125004124_png_a93a356a24.webp" alt="koyfin_20260723_125004124.png"><h2 class="st-heading-2">Big Pharma’s Patent Cliff Fuels Biotech M&amp;A</h2>The most powerful force behind the rebound is not simply improving investor sentiment, but it is Big Pharma’s urgent need for new drugs. Pharma companies have acquired 37 biotech businesses valued at $1 billion or more this year, already exceeding the previous annual record of 35, according&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/3778ec84-778f-4983-8ad9-85e7dbb5698d?syn-25a6b1a6=1">to</a> Stifel data cited by the Financial Times. Total biotech deal value has reached $216 billion, nearly doubling from $118 billion last year.The buying spree comes as several industry giants approach a steep patent cliff. Once exclusivity expires, cheaper generic or biosimilar competition can rapidly erode sales from blockbuster medicines.&nbsp;Morningstar&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.morningstar.com/business/insights/research/biopharma-landscape">estimates</a> that patent expirations could create a $139 billion revenue headwind for the largest biopharma companies through 2030. Keytruda, Merck’s top-selling cancer drug, and Bristol Myers Squibb’s Opdivo are among the major products facing patent pressure around 2028 and 2029. This leaves large drugmakers with two choices: develop replacements internally and accept years of clinical risk, or acquire companies whose drugs are already nearing approval or commercialization.<h2 class="st-heading-2">Big Pharma’s Buying Spree Tops $10B</h2>The buying spree has produced a string of multibillion-dollar deals targeting late-stage and commercially ready assets. Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, its largest-ever takeover, while AbbVie struck a $10.9 billion deal for Apogee Therapeutics' late-stage immunology pipeline. GSK paid $10.6 billion for Nuvalent to strengthen its oncology portfolio with two FDA-review lung cancer drugs.&nbsp;Eli Lilly, meanwhile, has emerged as the industry's most aggressive buyer, using obesity-drug windfalls to fund acquisitions across oncology, neuroscience and genetic medicines, most recently agreeing to acquire psychedelic drug developer AtaiBeckley for up to $3.8 billion.&nbsp;<h2 class="st-heading-2">Investors Hunt For Next Biotech Takeover</h2>With several high-profile targets already acquired, investors are looking for the next wave of biotech deals. Viking Therapeutics remains a leading candidate, with injectable and oral versions of obesity drug VK2735 offering buyers exposure to a GLP-1 market that Morningstar expects could approach $200 billion by 2035.Other potential targets include Structure Therapeutics, Revolution Medicines, Legend Biotech, Incyte, BioMarin, Ionis Pharmaceuticals and Moderna. Revolution Medicines offers a coveted RAS-targeted oncology pipeline, Legend provides commercial cell-therapy exposure through Carvykti, and Structure offers another route into oral obesity drugs. Syndax Pharmaceuticals and BioCryst Pharmaceuticals may also appeal to buyers seeking more de-risked commercial assets.Sellas Life Sciences (SLS) sits at the more speculative end of the watchlist. Its appeal hinges on the Phase 3 Regal trial of galinpepimut-S, or GPS, in AML. Sellas has recorded 78 of the 80 events needed to trigger the final analysis, putting it close to a pivotal readout. A positive survival outcome could boost its case as a late-stage oncology target. Its recent changes to executive change-of-control agreements have further fueled buyout speculation.<h2 class="st-heading-2">How Do Retail Traders Feel About XBI?</h2>On Stocktwits, retail sentiment toward XBI fell to a record-low score of 21 out of 100, shifting to ‘extremely bearish’ from ‘bearish’ a day earlier, amid ‘low’ message volume. The ticker’s watcher count has risen a modest 4% over the past year.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/xbi_ss_png_1dd85abfce.webp" alt="xbi ss.png" width="964" height="122"><figcaption>XBI sentiment and message volume as of July 23 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/JFDI/message/659748760">said</a>, “time for the $XBI to cool off and build out a handle.”<stembedurl>https://stocktwits.com/JFDI/message/659748760</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/The_Joker_has_Spoken/message/659692039">highlighted</a> an options open interest chart for XBI, suggesting that the heavy concentration of put open interest around the $150 strike could make it a key level to watch heading into the July 31 expiration.<stembedurl>https://stocktwits.com/The_Joker_has_Spoken/message/659692039</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-martin-shkreli-timing-aml-trial-data-wait-christmas/cZZnWveR7xB">SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas&nbsp;</a>

Biocryst Pharmaceuticals Inc.

Lilly(Eli) & Co

Merck & Co Inc

SELLAS Life Sciences Group Inc

Viking Therapeutics Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$ATAI $CMPS $LLY 

Just to clarify.  

You believe that Comp360 will become the gold standard, correct?

PS Maybe AI can help you with some paragraph breaks etc etc 😊

Usas Imbraer

$ATAI $CART See you at $100 to $130… the warning should be for you. Cover now or we’ll wreck you and your fellow shorts

Moneybag Joe

$ATAI what does it mean when my broker says i have recieved 2k CVRs due to a result of corporate action

Scrunchy

$ATAI my account shows my shares with .00001 average, but not showing any value? What happened here?

Feed

News

Sentiment

Earnings

Fundamentals

Info

ATAI AtaiBeckley Inc.

Fundamentals

Latest ATAI News